sarcosine has been researched along with Depression in 5 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression." | 9.41 | Ketamine, benzoate, and sarcosine for treating depression. ( Cheng, YJ; Lane, HY; Lin, CH, 2023) |
| "Glycine's effect was blocked by strychnine, a GlyR antagonist, indicating that it was mediated by strychnine-sensitive GlyRs." | 5.51 | Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats. ( Fu, R; Li, W; Ndukwe, M; Wu, L; Wu, W; Ye, JH; Zhang, H; Zuo, QK; Zuo, W, 2019) |
| "Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression." | 5.41 | Ketamine, benzoate, and sarcosine for treating depression. ( Cheng, YJ; Lane, HY; Lin, CH, 2023) |
| " In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment." | 5.17 | Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. ( Chang, YC; Chen, KT; Huang, CC; Huang, CL; Huang, KH; Lane, HY; Tsai, GE; Tsai, MH; Tsai, P; Tun, R; Wei, IH, 2013) |
| "Sarcosine, an N-methyl-d-aspartate receptor enhancer, can improve depression-like behavior in rodent models and depression in humans." | 3.85 | Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress. ( Chen, KT; Huang, CC; Jou, MJ; Tsai, MH; Wei, IH; Wu, CH; Wu, YC, 2017) |
| "Glycine's effect was blocked by strychnine, a GlyR antagonist, indicating that it was mediated by strychnine-sensitive GlyRs." | 1.51 | Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats. ( Fu, R; Li, W; Ndukwe, M; Wu, L; Wu, W; Ye, JH; Zhang, H; Zuo, QK; Zuo, W, 2019) |
| "N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement." | 1.43 | N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice. ( Chan, MH; Chen, HH; Chen, YC; Lee, MY; Lin, JC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YJ | 3 |
| Lin, CH | 3 |
| Lane, HY | 4 |
| Li, W | 1 |
| Zuo, W | 1 |
| Wu, W | 1 |
| Zuo, QK | 1 |
| Fu, R | 1 |
| Wu, L | 1 |
| Zhang, H | 1 |
| Ndukwe, M | 1 |
| Ye, JH | 1 |
| Huang, CC | 2 |
| Wei, IH | 2 |
| Huang, CL | 1 |
| Chen, KT | 2 |
| Tsai, MH | 2 |
| Tsai, P | 1 |
| Tun, R | 1 |
| Huang, KH | 1 |
| Chang, YC | 1 |
| Tsai, GE | 1 |
| Lin, JC | 1 |
| Chan, MH | 1 |
| Lee, MY | 1 |
| Chen, YC | 1 |
| Chen, HH | 1 |
| Wu, CH | 1 |
| Wu, YC | 1 |
| Jou, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sarcosine and Depression
| Article | Year |
|---|---|
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
Ketamine, benzoate, and sarcosine for treating depression.
Topics: Animals; Antidepressive Agents; Benzoates; Depression; Humans; Ketamine; Receptors, N-Methyl-D-Aspar | 2023 |
1 trial available for sarcosine and Depression
| Article | Year |
|---|---|
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
3 other studies available for sarcosine and Depression
| Article | Year |
|---|---|
Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats.
Topics: Action Potentials; Alcohol Drinking; Animals; Anxiety; Behavior, Animal; Depression; Glycine; Habenu | 2019 |
N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dose-Respo | 2016 |
Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Male; MAP Kinase Signaling Syste | 2017 |